Diagnostics
For the past year, Abbott Laboratories and Quest Diagnostics saw their revenue driven by COVID-19 diagnostics, but that seems to be changing as more and more vaccinated individuals are seeking medical advice for non-viral related issues.
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
This is the first confirmation of elemental metals in human brain tissue. Researchers hope it can contribute to the ongoing Herculean task of finding a cure for Parkinson’s and Alzheimer’s.
The newly approved drug, Lybalvi, is a once-daily oral antipsychotic drug that is both a maintenance monotherapy or for the acute treatment of manic or mixed episodes.
AbbVie is aiming Skyrizi and Rinvoq at various indications to augment expected declines in the use of its $20-billion-generating-powerhouse Humira, which will lose patent protection in 2023.
Two of Merck’s Phase III pediatric trials show 15-valent pneumococcal conjugate vaccine, V114, may be safe and effective in healthy children.
Please check out the biopharma industry’s COVID-19 stories that are trending for May 18, 2021.
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
Nearly 50 infants with “bubble baby” disease developed a working immune system after they received a gene therapy that contained the AIDS virus, according to a new study.
Two new venture capital funds, Droia Ventures and Perceptive Advisors closed on new funds to invest in early-stage life science companies.
PRESS RELEASES